Murine Monoclonal Antibodies against the Antimicrobial Peptide Oreoch-2 from Tilapia (Oreochromis niloticus)

Maylin Pérez-Bernal¹ , Onel Valdivia² , Reinaldo Blanco³ , Joel Pérez⁴ , ⁵ , y Domínguez⁶ , Liliana Basabe⁷ , Rebeca Martínez⁸ , Yeosvany Cabrera⁹

Section:Research Paper, Product Type: Journal-Paper
Vol.8 , Issue.1 , pp.32-35, Feb-2021

Online published on Feb 28, 2021

Copyright © Maylin Pérez-Bernal, Onel Valdivia, Reinaldo Blanco, Joel Pérez, ,y Domínguez, Liliana Basabe, Rebeca Martínez, Yeosvany Cabrera . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

View this paper at   Google Scholar | DPI Digital Library

XML View     PDF Download

How to Cite this Paper

Abstract :
Classic hybridoma technology has developed monoclonal antibodies (mAb) against a wide variety of antigens with several applications in biotechnology. In this work, murine mAb secreting hybridomas were generated for specific recognition of antimicrobial peptide Oreoch-2, isolated from tilapia and with demonstrated antimicrobial activity against bacteria and fungi. BALB/c mice were immunized with Oreoch-2 conjugated to bovine albumin. Cell fusion was performed between lymphocytes isolated from spleen of mouse with highest antibody serum titers and P3/x63.Ag8.653 myeloma cells. Three hybridomas with stable secretion of anti-P22 mAb were obtained, which did not show cross-reactivity with Oreoch-1 related peptide. The mAbs will be used in the study of the action mechanisms of antimicrobial peptide Oreoch-2 and to establish analytical tools for its detection and quantification in pharmaceutical formulations.

Key-Words / Index Term :
ascitic fluid, cell fusion, ELISA, hybridoma

References :
[1] K. Bermúdez, G. Hidalgo, R. Mora, C. Rodríguez, B. Ysmael-Acle, J. Mora, “Anticuerpos monoclonales biespecíficos: desarrollo, producción y anticancerígena,” Revista Médica de la Universidad de Costa Rica, Vol.13, No.1, pp.11-29, 2019.
[2] R. Seyfi, F. Kahaki, T. Ebrahimi, S. Montazersaheb, S. Eyvazi, V. Tarhriz, “Antimicrobial peptides (AMPs): roles, functions and mechanism of action,” International Journal of Peptide Research and Therapeutics, Vol.26, pp.1451-1463, 2020.
[3] M. González, J. San Juan, F. Morales, A. Otero, “Péptidos antimicrobianos: potencialidades terapéuticas,” Revista Cubana de Medicina Tropical, Vol.69, No.2, pp.1-13, 2017.
[4] J. Acosta, V. Montero, Y. Carpio, J. Velázquez, H. Garay, O. Reyes, A. Cabrales, Y. Masforrol, A. Morales, M. Estrada, “Cloning and functional characterization of three novel antimicrobial peptides from tilapia (Oreochromis niloticus),” Aquaculture, Vol.372, pp.9–18, 2013.
[5] J. Acosta, Y. Carpio, I. Valdés, J. Velázquez, Y. Zamora, R. Morales, A. Morales, E. Rodríguez, M. Estrada, “Co-administration of tilapia alpha-helical antimicrobial peptides with subunit antigen boosts immunogenicity in mice and tilapia (Oreochromis niloticus),” Vaccine, Vol.32, pp.223– 229, 2014.
[6] J. Acosta, M. Estrada, Y. Carpio, “Péptidos antimicrobianos aislados de tilapia (Oreochromis niloticus) como agentes terapéuticos y adyuvantes moleculares para peces y mamíferos,” Revista Anales de la Academia de Ciencias de Cuba, Vol.4, No.2, pp.1-20, 2014.
[7] G. Kohler, C. Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, Vol.256, pp.495-497, 1975.
[8] J. Gavilondo, “Anticuerpos monoclonales,” Elfos Scientiae, La Habana, pp.51-55, 1995.
[9] Y. Machado, “Caracterización de anticuerpos monoclonales funcionales específicos de ADAM-17,” Memory to qualify for the Degree of Doctor, Complutense University of Madrid, pp.85, 2017.
[10] N. Amin, N. Reyes, F. Camacho, O. Otero, M. Cuello, D. Núñez, S. Fernández, L. García, “Obtención de un anticuerpo monoclonal murino que reconoce al polisacárido capsular Vi de Salmonella Typhi,” VacciMonitor, Vol.24, No.2, pp.57-63, 2015.
[11] G. León, C. Cruz, L. Rojas, “Producción de anticuerpo monoclonal (AcMo) con especificidad anti B, para ser utilizado como reactivo de hemoclasificación,” Investigación clínica, Vol.45, No.2, pp.145-157, 2004.
[12] J. Trejos, J. Castaño, “Obtención de anticuerpos monoclonales de ratón contra proteasa de cisteína 5 recombinante de Entamoeba histolytica,” Revista MVZ Córdoba, Vol.17, No.2, pp.3014-3023, 2012.